Mayne Pharma (ASX:MYX) Receives Court Approval for Acquisition Scheme
Court Approval of Scheme Meeting
Mayne Pharma announced that the Supreme Court of New South Wales has approved the convening of a scheme meeting for shareholders to vote on Cosette Pharmaceuticals’ acquisition proposal.
Scheme Details
The scheme meeting is scheduled for Wednesday, 18 June 2025, at InterContinental Melbourne and online. Shareholders can vote via the online platform or appoint proxies.
Independent Expert’s Report
Deloitte Corporate Finance Pty Limited concluded the scheme is fair and in the best interests of Mayne Pharma shareholders, with the scheme consideration of $7.40 per share within the expert’s estimated range.
Directors’ Recommendation
The directors unanimously recommend shareholders vote in favour of the scheme, assuming no superior proposal and consistent expert conclusions.
Motley Fool contributor Abbie Stokes has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
This article was generated using GPT-4o mini, a Large Language Model (LLM), to generate summaries of investing news. While AI is generating the content, we know better than to blindly trust our future robot overlords, and every article is edited and fact-checked by an editor holding the appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content of everything published by The Capital Club.
